

**IN THE CLAIMS**

This listing of claims replaces all prior versions, and listings, in this application.

1. (original) A pharmaceutical formulation comprising: (a) an effective amount of levothyroxine sodium, (b) microcrystalline cellulose which has a mean particle size of less than 125 µm and is present in an amount of 60 to 85% w/w based upon the total weight of the formulation, and (c) pregelatinised starch present in an amount of 5 to 30% w/w based upon total weight of the formulation.
2. (previously presented) The pharmaceutical formulation as claimed in claim 1 wherein the microcrystalline cellulose has a mean particle size less than or equal to 100 µm.
3. (previously presented) The pharmaceutical formulation as claimed in claim 2 wherein the ratio of microcrystalline cellulose:pregelatinised starch is in the range of 2:1 to 15:1.
4. (currently amended) The pharmaceutical composition formulation as claimed in claim 3 wherein the microcrystalline cellulose and pregelatinised starch comprise water which is present in an amount 3-6% w/w based on the total weight of the formulation.
5. (previously presented) The pharmaceutical formulation as claimed in claim 1 wherein the levothyroxine sodium is hydrated.
6. (previously presented) The pharmaceutical formulation as claimed in claim 5 wherein the levothyroxine sodium is the pentahydrate form.
7. (previously presented) The pharmaceutical formulation as claimed in claim 1 which further comprises one or more glidant/lubricants.

8. (previously presented) The pharmaceutical formulation as claimed in claim 7 wherein the glidant/lubricants are selected from the group consisting of colloidal anhydrous silica, talc, magnesium stearate, and mixtures thereof.

9. (previously presented) The pharmaceutical formulation as claimed in claim 1 which is stable to the extent that potency decreases by less than 5% when the pharmaceutical formulation is stored at 25°C and 60% relative humidity for 12 months.

10. (previously presented) The pharmaceutical formulation as claimed in claim 1 in unit dose form.

11. (previously presented) The pharmaceutical formulation as claimed in claim 10 wherein the unit dose form is a tablet.

Claims 12-14 (canceled)

15. (withdrawn) A method of treating thyroid hormone disorders comprising administering a pharmaceutical formulation as claimed in claim 1 to a mammal.

16. (withdrawn-currently amended) A process for preparing a pharmaceutical formulation as claimed in claim 1 comprising (a) preparing a triturate of levothyroxine sodium, (b) mixing the triturate with [[the]] remaining components of the pharmaceutical formulation, and (c) compression compressing the mixture of triturate and remaining components.

17. (withdrawn) The method of claim 15 wherein said mammal is a human.

18. (new) The pharmaceutical formulation as claimed in claim 10 wherein the unit dose form is a 50 µg tablet which comprises: 0.0425-0.0575 mg levothyroxine sodium, 50-60

mg microcrystalline cellulose, 12-17 mg pregelatinised starch, 2-3 mg talc, 1-2 mg colloidal anhydrous silica and 0.5-1.0 mg magnesium stearate.

19. (new) The pharmaceutical formulation as claimed in claim 10 wherein the unit dose form is a 100 µg tablet which comprises: 0.085-0.115 mg levothyroxine sodium, 100-120 mg microcrystalline cellulose, 24-34 mg pregelatinised starch, 4-6 mg talc, 2-4 mg colloidal anhydrous silica and 1-2 mg magnesium stearate.